Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chandrasekhar Jaya, Kerkmeijer Laura S, Kalkman Deborah N, Sartori Samantha, Aquino Melissa B, Woudstra Pier, Beijk Marcel A, Tijssen Jan G, Koch Karel T, Hájek Petr, Atzev Borislav, Hudec Martin, Ong Tiong K, Mates Martin, Borisov Borislav, Warda Hazem M, den Heijer Peter, Wojcik Jaroslaw, Iñiguez Andres, Coufal Zdeněk, Khashaba Ahmed, Munawar Muhammad, Gerber Robert T, Yan Bryan P, Lee Michael, Baber Usman, Dangas George D, Colombo Antonio, de Winter Robbert J, Mehran Roxana, MASCOT and REMEDEE investigators (full list of collaborators shown in the Appendix)
Аннотация
METHODS AND RESULTS: We examined for sex differences in 1-year outcomes after COMBO stenting from the COMBO collaboration, a pooled patient-level dataset from the MASCOT and REMEDEE multicenter registries. The primary endpoint was 1-year target lesion failure (TLF), composite of cardiac death, target vessel-myocardial infarction (TV-MI), or clinically driven target lesion revascularization (CD-TLR). Secondary outcomes included stent thrombosis (ST). Adjusted outcomes were assessed using Cox regression methods. The study included 861 (23.8%) women and 2,753 (76.2%) men. Women were older with higher prevalence of several comorbidities including diabetes mellitus. Risk of 1-year TLF was similar in both sexes (3.8% vs. 3.9%, HR 0.92, 95% CI 0.59-1.42, p = .70), without sex differences in the incidence of cardiac death (1.6% vs. 1.5%, p = .78), TV-MI (1.5% vs. 1.1%, p = .32), or CD-TLR (2.0% vs. 2.2%, p = .67). Definite or probable ST occurred in 0.4% women and 1.0% men (HR 0.26, 95% CI 0.06-1.11, p = .069).
CONCLUSIONS: Despite greater clinical risks at baseline, women treated with COMBO stents had similarly low 1-year TLF and other ischemic outcomes compared to men.